This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Schultz et al.1 concluded that tetrabenazine (TBZ) use is not associated with depression or suicidality. This analysis of cross-sectional observational data from the Enroll-HD dataset contradicts prospective experimental evidence.2 This alone should caution against the authors' conclusion,1 but we have other concerns. Principally, 2 sources of bias may have distorted the observed associations. First, only individuals who tolerated TBZ are captured as users—those who abandoned treatment (e.g., due to depression/suicidality) are not counted. This survival bias would serve to induce a spurious negative association between TBZ use and depression/suicidality (i.e., a bias in the direction of an apparent protective effect). Second, antidepressant use may result from TBZ use (if this causes depression) and from depression itself (from other causes). Adjusting for this, as in this study,1 may introduce collider bias, and—again—a spurious negative association. These problems are compounded by the cross-sectional nature of the analysis, which precludes definition of incident depression/suicidality, despite prospective data being available within Enroll-HD. The conclusion that TBZ may be safe for patients with Huntington disease with a history of depression/suicidality is flawed and potentially dangerous. We welcome use of the Enroll-HD dataset, and CHDI Foundation funds an independent statistical standing committee to provide support and expertise (see supplemental full-length version, links.lww.com/WNL/A825).
Footnotes
Author disclosures are available upon request (journal{at}neurology.org).
- © 2019 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
